INTRODUCTION
============

The term delayed ejaculation (DE) (also called retarded ejaculation, inhibited ejaculation (IE), inadequate ejaculation, idiopathic anejaculation (AE), primary impotentia ejaculationis, or psychogenic AE) has been used to describe "a marked delay in or inability to achieve ejaculation" \[[@B1][@B2]\]. The term IE includes DE and AE. Segraves \[[@B3]\] criticized these terms as pejorative and is responsible for our current adoption of the term "delayed ejaculation." The "difficulty" experienced in ejaculating may range from varying delays in latency to AE. Despite the confusion in terminology, men diagnosed with DE experience difficulties in ejaculation and orgasm. Sometimes both may occur during self-masturbation or manual, oral, vaginal, or anal stimulation by the partner. In the Diagnostic and Statistical Manual of Mental Disorders (DSM), fifth edition, the definition of DE requires 1 of 2 symptoms: either a marked delay in or a marked infrequency or absence of ejaculation on 75% to 100% of occasions for at least 6 months of partnered sexual activity without the individual desiring delay, and causing significant distress to the individual \[[@B4]\].

In that document, the terminology DE is meant to describe any and all of the ejaculatory disorders that result in a delay or absence of ejaculation. Ejaculatory latency is defined as the time it takes for a man to achieve ejaculation. For research purposes, this is often defined as the intravaginal ejaculation latency time (IELT), which is the time taken by a man to ejaculate during vaginal penetration. The Third International Consultation on Sexual Medicine defined DE as an IELT threshold beyond 20 to 25 minutes of sexual activity, as well as negative personal consequences such as bother or distress \[[@B5]\]. The 20- to 25-minute IELT criterion was chosen primarily because it represents a threshold of more than 2 standard deviations above the mean found in population-based studies of IELT. However. Perelman \[[@B6][@B7]\] criticized this time frame for ignoring 2 important findings: a) most men seeking help for DE pursue treatment because of its impact on coitus, and b) most men\'s IELT range is approximately 4 to 10 minutes \[[@B8][@B9][@B10]\]. Any bilateral deviation from the \~4- to 10-minute IELT range of the majority of men should meet the qualification for the temporal diagnostic criterion. Accordingly, Perelman \[[@B7]\] suggested the following definition for coital DE: a) inability/incapacity to choose to ejaculate intravaginally in less than \~10 minutes in all, or nearly all, coital encounters; b) not having the ability/capacity to choose to ejaculate sooner, but desiring the ability to do so; and c) experiencing negative personal consequences, such as distress, bother, frustration, and/or the avoidance of sexual intimacy. There seems to be a general agreement that low rates of DE are reported in the literature, and it appears to be the least common form of male sexual dysfunction. The prevalence rate of DE among the general population ranges from 1% of sexually active men (lifelong DE) to 5% (acquired DE) \[[@B11][@B12][@B13][@B14][@B15][@B16][@B17]\].

Some previous studies were carried out according to the DSM-III \[[@B16]\] and International Classification of Diseases, 10th edition \[[@B17]\] diagnostic criteria. The lack of an internationally accepted universal definition, combined with the absence of consensus about normative data for defining the duration of "normal" ejaculatory latency and the lack of a distinction between various types of delayed ejaculatory disorders (*e.g.*, delayed *vs.* absent) among epidemiologic studies, limits our knowledge regarding the true prevalence of DE. Nonetheless, DE appears to be positively related to age \[[@B18][@B19][@B20]\], and its prevalence differs among races \[[@B17]\]. While some women enjoy the prolonged IELT, others may experience pain, question their own attractiveness, or suspect the partner\'s infidelity \[[@B21]\]. Although clinical advances have been made in the diagnosis and treatment of erectile dysfunction, there is a consensus that DE/AE is still a poorly understood disorder, with inconsistent practice patterns seen among practicing physicians \[[@B22]\]. This article aims to review the pathophysiology of DE/AE, to explore our current understanding of the diagnosis, and to present the treatment options for this condition.

ETIOLOGY AND PATHOPHYSIOLOGY
============================

Ejaculation involves emission, bladder neck closure, and expulsion (ejaculation proper). In emission, seminal fluid is delivered to the posterior urethra. Sympathetic innervation (T10\~L2) controls the emission, as well as contraction of the bladder neck to prevent retrograde ejaculation. During expulsion, the bulbocavernosus muscle, synchronized with the pelvic floor muscles, contracts to expel semen in an antegrade fashion through the anterior urethra. Somatic innervations (S2\~S4) mediate this process. Generally, this reflex is controlled by both sympathetic and somatic neural inputs, as well as sensory inputs. Many neurotransmitters such as serotonin, dopamine, and norepinephrine play roles in ejaculatory physiology. Orgasm is a purely cerebral experience that usually, but not always, coincides with ejaculation. For many years, different views have existed regarding the etiology of DE/AE ([Table 1](#T1){ref-type="table"}). On one hand, it was argued that DE may be caused by psychosexual, psychosocial, or relationship problems. On the other hand, it has been argued that DE is caused by genetic, neurobiological, endocrine, anatomic, and infectious factors, or may be drug-induced. Many of these etiologic factors are not supported by good evidence-based data, but rather are based on case reports and case series. These etiological factors---organic and psychogenic etiologies---are neither independent nor mutually exclusive and may well interact with each other, and their pathological effects may vary between individuals \[[@B1][@B2][@B13]\].

1. Psychogenic factors
----------------------

Multiple proposed psychogenic factors may contribute to the pathogenesis of DE ([Table 1](#T1){ref-type="table"}). Althof \[[@B23]\] summarized these proposed psychogenic factors into 4 theories based on empirical support:

1\) Insufficient sexual stimulation (mental and physical). This theory was proposed by Masters and Johnson \[[@B24]\] and Bancroft \[[@B25]\]. This theory perceives DE as being due to insufficient penile or mental stimulation, often associated with aging or diminished penile sensation. The main predictions of this theory were supported by findings from multiple studies \[[@B26][@B27][@B28]\]. Rowland et al \[[@B26]\] reported that men with DE had no apparent somatic etiology and experienced less sexual arousal than normal men. Teloken et al \[[@B27]\] performed an analysis of data from 206 patients who presented with secondary delayed orgasm/anorgasmia and noted abnormal penile sensation in 7%. Additionally, Xia et al \[[@B28]\] noted that patients with primary DE appeared to have penile shaft, rather than glans, hyposensitivity and hypoexcitability. Furthermore, Nelson et al \[[@B29]\] confirmed that penile vibratory stimulation (PVS) could adequately treat 72% of patients with secondary DE and orgasm, indicating that PVS may initiate the normal ejaculatory reflex.;

2\) Unusual masturbation patterns and fantasy life. This theory stated that some men with DE tend to prefer unusual methods of masturbation over heterosexual intercourse with their partner. Perelman and Rowland \[[@B14]\] and Perelman \[[@B30]\] identified 3 factors that disproportionately characterized patients with DE: a) high-frequency masturbation (age-dependent mean of greater than 3 times per week), b) idiosyncratic masturbatory style (masturbation technique not easily duplicated by the partner\'s hand, mouth, or vagina), and c) disparity between the reality of sex with a partner and their preferred masturbatory fantasy.;

3\) The concept of the third psychological theory was posited by Apfelbaum \[[@B31][@B32]\]. It conceptualizes DE as a subtle and disguised sexual desire disorder masquerading as DE. According to this concept, these patients mainly prefer solo masturbation, rather than partnered sex.;

And 4) the fourth theory considers DE as an outgrowth of a psychic conflict, making it psychodynamic in origin. The following conflicts have been reported: a) different types of fear (see [Table 1](#T1){ref-type="table"}); b) hostility toward one\'s partner; c) unwillingness to give oneself; and d) guilt from a strict religious upbringing \[[@B23]\].

2. Organic factors
------------------

Any congenital abnormality, medical disease, surgical procedure, or drug that interferes with either central control of ejaculation or the peripheral control that includes sympathetic nerve supply to the vas deferens, bladder neck, prostate or seminal vesicles, as well as the somatic efferent nerve supply to the pelvic floor, can result in DE/AE and anorgasmia \[[@B5]\]. Many reports on DE/AE have been published, but several terminological discrepancies have caused controversy ([Fig. 1](#F1){ref-type="fig"}). Several studies have reported that that DE/AE may be caused by several factors, including aging-related, congenital, genetic, neurogenic, infection/inflammation, endocrine, and pharmacologic causes ([Table 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}).

### 1) Aging

An age-dependent increase in the prevalence of DE was reported in various studies \[[@B33][@B34][@B35]\]. This finding may be related to decreased penile sensitivity with age, which has been attributed to possible ultrastructural or degenerative age-related changes in the penile receptors \[[@B36][@B37][@B38]\], leading to progressive axonal sensory loss \[[@B39][@B40]\]. Other factors include age-related comorbidities, such as depression, diabetes, or late-onset hypogonadism \[[@B19]\], or medical, surgical, or radiation therapy for a number of age-related diseases that can affect ejaculatory function \[[@B41][@B42]\]. Additionally, some researchers have hypothesized that DE is caused, at least in part, by slower bulbocavernous reflexes and reduced spinal stimulation associated with aging \[[@B43][@B44]\]. Despite these age-related changes, Paduch et al \[[@B15]\] failed to show a significant correlation between DE and age (odds ratio=0.67; 95% confidence interval, 0.39\~1.16; p=0.149) in a prospective observational study of 988 subjects.

3. Genetic factors
------------------

DE is marked by etiological complexity (it is multifactorial and many cases are idiopathic), and a range of severity from DE to AE \[[@B1][@B5][@B45]\]. In addition, ejaculatory latency is greatly variable \[[@B8][@B10]\]. These findings have led to the hypothesis that genetic factors can affect a person\'s predisposition to DE/AE. Unfortunately, a Finnish twin study showed that genetics influenced premature ejaculation (PE), but not DE \[[@B46]\]. In contrast, Jern et al \[[@B47]\] documented that the single-nucleotide polymorphism (SNP) rs11568817 in the gene encoding the 5-HT~1B~ receptor showed an association with IELT, indicating that individuals homozygous for the G allele had a shorter IELT, conferring protection against DE. In another study, Jern et al \[[@B48]\] noted that a SNP for the oxytocin receptor gene OXTR (rs75775) was associated with differences in self-reported IELT and perceived ejaculatory control suggesting that heterozygotes had an elevated risk of a shorter IELT, conferring protection against DE ([Table 2](#T2){ref-type="table"}). These results suggest that this topic may warrant further investigation.

Patients who receive serotonergic antidepressants frequently report sexual dysfunction. A very high elevated risk (7-fold) for DE/AE was observed in selective serotonin reuptake inhibitor (SSRI) users \[[@B49]\]. The significant heterogeneity in the occurrence and the presentation of SSRI-related sexual dysfunction may suggest underlying genetic factors \[[@B50]\]. Several studies have applied genomic techniques to identify candidate genes and potential genetic risk factors for SSRI-induced DE/AE, utilizing either the candidate gene approach (genotyping of a limited number of genes) \[[@B51][@B52][@B53][@B54][@B55][@B56][@B57][@B58]\] or the genome-wide association approach (genotyping of hundreds of thousands of polymorphisms) \[[@B59][@B60][@B61]\]. [Table 2](#T2){ref-type="table"} summarizes the results of these studies. No group of polymorphisms has been consistently demonstrated to explain a relevant proportion of the variance in SSRI-induced DE/AE. These findings require replication before firm conclusions can be drawn.

4. Neurobiological factors
--------------------------

Waldinger et al \[[@B62]\] and Waldinger and Schweitzer \[[@B63]\] introduced a dynamic neurobiological theory of PE and DE. According to this "ejaculation distribution theory," lifelong DE, as well as PE, is considered to be part of a normal biological variability in IELT. It is postulated that any random sample of men is likely to include a minority of men with (nearly) always early ejaculation, and a second minority who (nearly) always suffer from DE, while the majority have a "normal" or "average" IELT. The finding of significant variability in IELT values among the general population---from 0.55 to 44.1 minutes---supports this theory \[[@B8][@B10]\]. Men with a genetically determined higher ejaculatory threshold set point could sustain more prolonged and intense sexual stimulation and could exert more control over ejaculation \[[@B64]\]. Accordingly, life-long (primary) DE with a very high set point, like lifelong PE, is considered to be primarily a neurobiological variant. Presumably, affected individuals suffer from a susceptibility that interacts with a variety of psychosocial, environmental, cultural, and medical risk factors to result in DE \[[@B6]\]

5. Other organic causes
-----------------------

The list of organic causes possibly leading to DE/AE is extensive and is outlined in [Table 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}. A full discussion of each factor is beyond the scope of this review. New etiologies continue to be added to the list of causes. "Difficulty" in ejaculating has been reported in patients with congenital abnormalities that may compromise the functions of the vas deferens, ejaculatory duct, prostate, seminal vesicle, and urethra \[[@B65][@B66][@B67][@B68]\].

The neurological mechanisms that lead to DE/AE are damage to the sympathetic ganglia and/or injury of post-ganglionic sympathetic nerve fibers to the organs of emission, mainly as a result of a neuro-logic disease, trauma, or pelvic surgery ([Table 1](#T1){ref-type="table"}). Additionally, DE/AE is common in patients with pelvic cancer treated with radiation therapy. DE was reported by 40% of 109 prostate cancer patients who received a radiation dose of 78 Gy (Gray, 1 Gy=100 rad), while AE was reported by 11% of patients \[[@B69]\]. The prevalence of ejaculatory dysfunction appears to increase as time elapses after radiation therapy. In a previous study, the proportion of patients experiencing AE 1, 3, and 5 years after radiation therapy was 16%, 69%, and 89%, respectively \[[@B70]\]. In these circumstances, DE/AE may be associated with decreased sensitivity in the penis \[[@B69]\]. However, the influence of these neurological factors on ejaculation is due to more than just neurological reasons, as the accessory sexual glands and pathway for semen are removed or injured during radical pelvic surgery. Moreover, sexual dysfunction is a multidimensional construct of numerous bio-psychosocial factors that can be influenced by surgery in a variety of ways, including impacts to a patient\'s cosmetic appearance, psychological state, preoperative radiation, stoma formation in rectal cancer, surgical complications, and increased age.

While DE/AE occurs in up to 17.9% of multiple sclerosis patients \[[@B71]\], the majority of patients with spinal cord injury (SCI) (52%) cannot ejaculate during sexual intercourse \[[@B72]\]. Even though diabetes mellitus is considered to be a known cause of DE/AE, the true incidence of these conditions in individuals with diabetes is unclear. In a population-based study \[[@B73]\] inability to reach orgasm with masturbation was slightly more prevalent (21.1%) in diabetic subjects than in those without diabetes (14.9%). The most common causes of AE are retroperitoneal lymph node dissection and SCI, which jointly account for almost 90% of cases \[[@B74]\].

Erectile dysfunction, PE, and painful ejaculation are the leading sexual symptoms of urogenital infections. However, there is no definitive evidence of the actual frequency of DE/AE in patients with urogenital infections or of the true pathophysiological role of these inflammatory disorders in ejaculatory delay \[[@B75]\]. Urogenital infections can produce scarring and obstruction anywhere in the male reproductive tract. Disorders affecting levels of testosterone (T), prolactin, and thyroid hormone have also been associated with DE/AE. T appears to play a facilitatory role in the control of the ejaculatory reflex \[[@B76]\], but estimated ejaculation times during vaginal intercourse and/or masturbation were not associated with serum T levels in a recent study \[[@B77]\]. Once again, there is weak evidence of an association between hyperprolactinemia and DE \[[@B78]\]. In contrast, hypothyroidism was strongly associated with longer IELT (DE), while shorter IELT (PE) was linked to hyperthyroidism \[[@B35][@B79]\].

Complaints of DE/AE in patients taking medications are not uncommon. Different medications may interfere with either central or peripheral control of ejaculation, potentially affecting the IELT ([Table 3](#T3){ref-type="table"}). Pharmacological agents that have been associated with DE/AE include tricyclic antidepressants, SSRIs, monoamine oxidase inhibitors, neuroleptics, diuretics, narcotics, alpha 1-blockers, antiepileptics, 5-alpha reductase inhibitors, alcohol, and others \[[@B41][@B80]\]. The literature suggests that DE/AE is the most commonly reported sexual dysfunction associated with antidepressant use; other frequently reported problems include delayed and/or absent orgasm, reduced and/or absent sexual desire, and erectile dysfunction.

DIAGNOSIS
=========

Unfortunately, there is currently no single gold standard for diagnosing DE/AE, as operationalized criteria do not exist \[[@B3][@B7][@B22]\]. Because many organic and psychological factors may be involved in the pathogenesis of DE/AE, a careful clinical history and appropriate physical examination should focus on all related symptoms and signs. A list of an assessment steps that might be helpful in the evaluation of the patient is presented in [Fig. 2](#F2){ref-type="fig"}. The history is the key to the diagnosis of DE/AE. Evaluation begins by exclusion of retrograde ejaculation, absence of puberty, genital tract obstruction, anorgasmia, and other sexual dysfunctions that may be misdiagnosed as DE/AE, such as erectile dysfunction, a subtly decreased libido, ejaculatory pain, the partner\'s sexual dysfunction, sexual orientation conflicts, or paraphilic inclinations/interests. It is important in the history to ascertain whether the complaint concerns DE/AE, the sensation of orgasm, or both. Ejaculation occurs in the genitals, whereas orgasm is a central sensory event with significant subjective variation. Ejaculation and orgasm usually occur together, but not always. The sensation of orgasm in the absence of antegrade ejaculation suggests retrograde ejaculation, absence of puberty, or genital tract obstruction. The second step is to confirm the presence of DE/AE by asking about the duration of thrusting before suspension of intercourse, the ability to advance the ejaculatory response, and the level of distress or bother caused by this situation. The evaluation may involve determining whether DE is lifelong or acquired and global or situational. In the generalized form (lifelong or acquired), the history may reveal whether the patient is experiencing substantial delay or absence of ejaculation/orgasm in all circumstances. In a considerable number of cases of DE/AE, the patient is typically unable to ejaculate in the presence of a partner (especially during coitus) but is able to orgasm and ejaculate during solo masturbation. If a man is only able to ejaculate through masturbation, it is important to assess whether he has an idiosyncratic masturbatory style \[[@B7][@B21]\]. Men with DE/AE have demonstrated high levels of relationship distress, sexual dissatisfaction, anxiety about their sexual performance, and lower frequencies of coital activity than sexually functional men \[[@B21][@B28][@B81]\]. The third step is to uncover the predisposing issues and the potential risk factors that are believed to participate in the pathogenesis of DE/AE. A focused clinical examination, questionnaires (such as Male Sexual Health Questionnaire, International Index of Erectile Function, and others), laboratory tests, and radiologic imaging may help diagnose these potential risk factors ([Table 1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}, [Fig. 2](#F2){ref-type="fig"}).

Physicians need to carefully balance the risk of missing serious causes with the wise use of often scarce and costly investigative resources, especially in developing countries. Sometimes the diagnosis of the risk factor(s) unfolds over time and across several episodes of care. In addition, the etiologic diagnostic process can also extend across multiple specialties and in different locations.

TREATMENT
=========

Defining firm recommendations to approach the treatment of DE/AE is difficult for a condition that is less common and heterogeneous, for which the literature is confined to case reports, case series, and small studies. There are many approaches to treatment planning. A rigid treatment plan is not suitable for all patients. Factors that affect the choice of treatment strategies may include:

1\) Clinical judgment regarding the etiology of DE/AE and making sound decisions. This implies the active involvement of other specialties in the management of the condition.;

2\) The physician\'s experience, such as training in communication skills and the management of sexual problems. These factors have been shown to affect professional behavior \[[@B82]\].;

3\) The medical, anatomical, pharmacologic, and surgical risks associated with DE/AE. In these cases, treatment should be cause-specific. Neurogenic AE is usually irreversible, and thus the patient might be counseled to seek alternative methods to improve patient and partner satisfaction. A positive cremasteric reflex in patients with SCI suggests intact emission, and patients should be encouraged to attempt ejaculation or to explore possible retrograde ejaculation \[[@B83]\]. In a recent randomized controlled trial \[[@B84]\], a 2% replacement T solution was not associated with significant improvement in DE/AE in androgen-deficient men, suggesting that androgen deficiency is not the sole contributor to ejaculatory dysfunction. In contrast, a pharmaceutical company-sponsored multicenter randomized, double-blind controlled trial \[[@B85]\] showed improvement of ejaculatory function in hypogonadal men receiving a 2% T solution. Unfortunately, in the latter study, ejaculatory dysfunction was not one of the inclusion criteria. Autonomic and somatic nerve preservation is indispensable to minimize postoperative sexual sequelae regardless of the surgical approach (posterior, lateral, anterior, or perineal dissection). When the hypogastric and homolateral pelvic plexuses are preserved unilaterally, ejaculation is preserved in 25% to 47% of cases, but when the pelvic plexus is preserved partially but the hypogastric nerve is not, ejaculation is maintained in 0% of patients. In contrast, when the pelvic autonomic nerves are completely preserved, ejaculation is preserved in 55% to 83% of patients \[[@B86][@B87]\].;

4\) The presence of co-occurring mental disorders, sexual orientation conflicts, unusual masturbation techniques, strong religious convictions, hostility, fears, relationship factors, or paraphilic inclinations/interests must be assessed because these factors may narrow the scope of possible treatment strategies and help the physician identify whether psychiatric care is needed.;

5\) Consultation with a gynecologist may have a significant impact on cases associated with the partner\'s sexual dysfunction or other gynecological disorders, as DE/AE may be triggered by the fear of hurting the partner or a decrease in the perceived attractiveness of the partner, if she has had a mastectomy, hysterectomy, or other types of disfigurement.;

6\) If fertility is an issue, it can be managed relatively efficiently in cases of AE with collection of nocturnal emissions, PVS, rectal probe electroejaculation (EEJ), and/or microsurgical sperm aspiration \[[@B88][@B89]\]. Men of reproductive age should be informed of the risk of infertility due to AE following radical pelvic surgery and the need for sperm harvesting and assisted reproductive techniques.;

7\) Patient preferences are an important consideration in the treatment of DE/AE. For example, a patient\'s preference preference regarding the partner\'s participation is more critical to successful outcomes than the partner\'s attendance at all office visits \[[@B90]\].;

And 8) success depends on the patient\'s willingness and capacity to follow various interventions \[[@B6]\].

1. Psychological interventions
------------------------------

Paying special attention to psychogenic factors may additionally reinforce the therapeutic success of some patients. Many psychotherapeutic treatments have been described for the management of DE/AE, addressing known or suspected psychogenic causes \[[@B6][@B23][@B30][@B31][@B32][@B45]\]. These include but not limited to: a) cognitive behavioral therapy and sex education; b) masturbatory retraining and adjustment of sexual fantasies; c) psychotherapy targeting the areas of conflict and sensate focus exercises; d) altering one\'s orientation from oneself to one\'s partner; e) sexual anxiety reduction by teaching the individual mindfulness and breathing techniques, progressive relaxation, and increasing sensory tolerance; f) couples\' sex therapy and the use of interactional techniques; and g) the sexual tipping point model, which emphasizes the utility of a biopsychosocial-cultural perspective combined with special attention to the patient\'s narrative. Treatment is patient-centered and holistic, and integrates a variety of therapies as needed \[for more details see ref. [@B6]\]. Generally, these psychological maneuvers appear to be effective in case reports and case series but none have been properly evaluated in large-scale studies.

2. Pharmacotherapy
------------------

Attempts have been made to treat DE/AE using off-label medications based on pharmacological and physiologic considerations \[[@B91][@B92][@B93]\]. However, an approved drug does not exist. These medications facilitate ejaculation by different mechanisms of action ([Table 4](#T4){ref-type="table"}), have limited success, and may lead to significant side effects.

Given the variety of drugs available for managing DE/AE, the question of which to choose can be a complicated issue in clinical practice. The choice of drug should be guided by etiologic factors, illness characteristics (DE or AE), the patient\'s preferences, the clinical evidence, and the physician\'s comfort with different drugs. It is known that the response is relatively poor in neurogenic DE/AE. Of interest is the recent single-case report of the successful oral administration of 60 mg of lisdexamfetamine dimesylate (a prodrug that is converted by the liver to the active dextroamphetamine. which is a noncatecholamine, sympathomimetic amine) 2 hours prior to masturbation in a patient with neurogenic AE \[[@B92]\]. In contrast, a recent double-blind randomized placebo-controlled small study \[[@B94]\] showed that midodrine was similar to placebo in inducing antegrade ejaculation in patients with SCI. For patients who suffer from antidepressant-related DE/AE, shifting to another antidepressant such as bupropion or adding cabergoline if they have hyperprolactinemia may be the most prudent option. For patients with idiopathic DE, symptomatic management with a drug or a combination of drugs aimed at more than 1 therapeutic target may be an option of choice. Hence, the selection of a drug should be tailored to the needs of individual patients and the specific circumstances of each case. Generally, drug treatment does not always produce normal ejaculation, but it may enable partial antegrade ejaculation or retrograde ejaculation.

3. Treatment of infertility issues
----------------------------------

Here again, a number of approaches can be employed. The simplest approach is to collect nocturnal emissions in a spermicide-free condom for assisted reproduction \[[@B88]\]. Some patients may report sporadic events of nocturnal emission or ejaculation induced by severe emotional excitement unrelated to sexual activity. A second, simple approach to obtain spermatozoa from psychogenic AE is through vigorous prostatic massage \[[@B95]\] or prostatic urethra catheterization \[[@B96]\]. The presence of spermatozoa in the prostatic urethra may be due to ejaculation dyssynergia ([Fig. 1](#F1){ref-type="fig"}). Assisted ejaculation in the form of PVS is the next choice for sperm retrieval in idiopathic AE and is the first choice in neurogenic AE because it is noninvasive and inexpensive \[[@B97]\]. It requires an intact lumbosacral cord segment. Spinal cord lesions above T10 suggest a better response. In patients in whom PVS fails, EEJ may be successful \[[@B89]\]. The adverse effects profile of these procedures may include skin irritation, high blood pressure, rectal mucosa burning, and autonomic dysreflexia, which can be pretreated with 10 to 40 mg of sublingual nifedipine approximately 15 minutes prior to PVS, which can blunt the increase in blood pressure in men with a history of SCI. In the vast majority of these men, motile spermatozoa can be obtained through assisted ejaculation. When such procedures fail, sperm retrieval through either percutaneous vasal sperm aspiration or minimally invasive epididymal sperm aspiration may be an option \[[@B98]\]. Ejaculate samples retrieved from men with SCI typically are characterized by a normal sperm concentration, but abnormally low sperm motility and viability. Despite the impaired sperm parameters, the pregnancy outcomes of assisted reproduction using sperm from men with SCI are similar to those using sperm from non-SCI men. In cases with azoospermia, testicular sperm extraction for intracytoplasmic sperm injection is a feasible option \[[@B99]\]. Approaches for sperm recovery should be considered and employed in a step-wise fashion, starting with the most cost-effective and least invasive options \[[@B98]\]. The patient should realize that with any approach for sperm recovery there is some risk of hematoma, infection, or pain, all of which are likely to resolve with time.

CONCLUSIONS
===========

The literature suggests that the pathophysiology of DE/AE is multifactorial, including both organic and psychosocial factors that are neither independent nor mutually exclusive. Despite the many publications on this condition, the exact pathogenesis is not yet known. There is currently no single gold standard for diagnosing DE/AE, as operationalized criteria do not exist. The history is the key to the diagnosis. Treatment should be cause-specific. There are many approaches to treatment planning, including various psychological interventions, pharmacotherapy, and specific treatments for infertile men. No approved drug therapy exists. A rigid treatment plan is not suitable for all patients. A number of approaches can be employed for infertile men, including collection of nocturnal emissions, vigorous prostatic massage, prostatic urethra catheterization, PVS, rectal probe EEJ, sperm retrieval from either the vas deferens or the epididymis, or testicular sperm extraction.
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###### Etiological factors that may be involved in the pathophysiology of delayed ejaculation and anejaculation

![](wjmh-36-22-i001)

  I. Psychosexual and psychosocial factors                                                                  II\. Organic and biological factors
  --------------------------------------------------------------------------------------------------------- --------------------------------------------------------
  a\. Fears:                                                                                                Aging
   - Fear of pregnancy and fertility issues                                                                 
   - Fear of castration and death                                                                           
   - Fear of annihilation associated with loss of semen                                                     
   - Fear of loss of control                                                                                
   - Fear of exposure and subsequent shame concerning the problem                                           
   - Fears of abandonment/rejection                                                                         
   - Fears of intimacy and loss of autonomy                                                                 
   - Fears of hurting/defiling the partner                                                                  
   - Fear of retaliation by the female or by other males                                                    
   - Success phobia                                                                                         
  b\. Sexual orientation conflicts                                                                          Genetic factors (see [Table 2](#T2){ref-type="table"})
  c\. Hostility and resentment                                                                              Neurobiological factors
  d\. Obsessive-compulsive personality traits                                                               Congenital anatomical factors:
   • Müllerian duct cyst                                                                                    
   • Wolffian duct abnormalities                                                                            
   • Prune belly syndrome                                                                                   
   • Posterior urethral valves                                                                              
   • Complete male epispadias                                                                               
   • Bladder exstrophy                                                                                      
   • Sacral Tarlov cyst                                                                                     
   • Imperforate anus                                                                                       
   • Seminal megavesicle                                                                                    
  e\. Performance anxiety                                                                                   Neurogenic causes:
   • Diabetic autonomic neuropathy                                                                          
   • Multiple sclerosis                                                                                     
   • Spinal cord injury                                                                                     
   • Radical prostatectomy                                                                                  
   • Pelvic radiation therapy                                                                               
   • Proctocolectomy                                                                                        
   • Bilateral sympathectomy                                                                                
   • Abdominal aortic aneurysmectomy                                                                        
   • Para-aortic lymphadenectomy.                                                                           
   • Pelvic fracture-urethral distraction defect injury                                                     
   • Adult circumcision                                                                                     
  f\. Lack of self-assertion                                                                                Infection/inflammation:
   - Urethritis                                                                                             
   - Genitourinary tuberculosis                                                                             
   - Schistosomiasis                                                                                        
   - Prostatitis                                                                                            
   - Orchitis                                                                                               
   - Orchialgia in testis cancer survivors                                                                  
  g\. An unwillingness to give of oneself in love                                                           Endocrine:
   - Hypogonadism                                                                                           
   - Hypothyroidism                                                                                         
   - Hyperprolactinemia                                                                                     
  h\. Strong religious convictions, leading to guilt                                                        Medications ([Table 3](#T3){ref-type="table"})
  i\. Autosexual orientation:                                                                               
   - Positive reinforcement associated with self-masturbation                                               
  j\. Unusual masturbation techniques:                                                                      
   - High-frequency masturbation                                                                            
   - Idiosyncratic and vigorous masturbation style                                                          
   - Disparity between the reality of sex with a partner and preferred sexual fantasy during masturbation   
  k\. Relationship factors:                                                                                 
   - Disparity between fantasy and partner                                                                  
   - Partner sexual dysfunction                                                                             
  l\. Diminished sexual desire                                                                              
  m\. Insufficient sexual arousal and female sexual dysfunction                                             
  n\. Depression and other psychiatric diseases                                                             

###### Summary of genetic polymorphisms that may have potential roles in DE/AE, especially SSRI-induced DE
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  Gene (Reference No)                                           Polymorphism or alleles                                                                                                                                                Diagnosis                                                                  Drug(s)                                                             Measurement and type of sexual dysfunction                                    Main result
  ------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------- ------------------------------------------------------------------- ----------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *CYP 2D6* \[[@B51]\]                                          *CYP2D6^\*^1*                                                                                                                                                          Depressive disorders                                                       Paroxetine                                                          \- ASEX                                                                       DE was reported by poor metabolizers.
  *CYP2D6^\*^3*                                                 \- Different types                                                                                                                                                                                                                                                                                                                                                                                  
  *CYP2D6^\*^4*                                                 \- Men (n=9)/women                                                                                                                                                                                                                                                                                                                                                                                  
  *CYP2D6^\*^5*                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *CYP2D6^\*^6*                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *CYP 2D6* \[[@B53]\]                                          *CYP2D6^\*^1*                                                                                                                                                          Depressive disorders, anxiety disorder                                     Paroxetine                                                          \- ASEX                                                                       Negative results in men
  *CYP2D6^\*^3*                                                 \- Different types                                                                                                                                                                                                                                                                                                                                                                                  
  *CYP2D6^\*^4*                                                 \- Men (n=20)/women                                                                                                                                                                                                                                                                                                                                                                                 
  *CYP2D6^\*^5*                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  *CYP2D6^\*^6*                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  \- 5HT~2A~ receptor \[[@B52]\]                                \- 5HT~2A~                                                                                                                                                             Depressive disorders                                                       SSRIs                                                               \- Different types                                                            \- 5HT~2A~
  \- 1438 G/A (rs6311)                                          \- Men (n=20)/women                                                                                                                                                    \- 1438 GG genotype was a significant predictor of lower arousal scores.                                                                                                                                                     
  \- *GNB3* gene \[[@B52]\]                                     *GNB3* 825 C/T (rs5443)                                                                                                                                                Depressive disorders                                                       SSRIs                                                               \- Different types                                                            No significant relationship
  \- Men (N=20) /women                                                                                                                                                                                                                                                                                                                                                                                                                                              
  *SLC6A4* \[[@B55]\]                                           5HTTLPR                                                                                                                                                                Men and women with depression                                              Escitalopram or nortriptyline                                       Antidepressant side-effects, SFQ                                              HTTLPR was not associated with sexual dysfunction.
  68 candidate genes \[[@B54]\]                                 68 candidate genes related to dopamine, serotonin, adrenergic receptors, glutamate, and neurotrophins as well as other signaling pathways and second-messenger genes   Caucasian men and women with major depressive disorder                     Citalopram                                                          PRISE                                                                         *GRIA1* was associated with difficulty achieving orgasm.
  *HTR~2A~* \[[@B56]\]                                          *HTR~2A~* -1438A\>G (rs6311)                                                                                                                                           Han Chinese men with major depressive disorder                             SSRI or venlafaxine (SNRI)                                          ASEX                                                                          *HTR~2A~* -1438 A/A genotype was associated with sexual dysfunction.
  Many genes \[[@B59]\]                                         Genome-wide study examining \~186,000 SNPs                                                                                                                             Japanese men and women with major depression                               Paroxetine, fluvoxamine, milnacipran (SNRI)                         \- Clinician\'s assessment                                                    *GRIA3*, *GRIA1*, *GRIN3A*, and *GRIK2* were not associated with sexual dysfunction, including DE
  \- Different types                                            \- SNPs in *MDGA2* were associated with sexual dysfunction.                                                                                                                                                                                                                                                                                                                                         
  \- Men (n=106)/women                                                                                                                                                                                                                                                                                                                                                                                                                                              
  *ABCB1* \[[@B57]\]                                            rs1045642                                                                                                                                                              Depressive and anxiety disorders                                           Citalopram, paroxetine, venlafaxine, fluvoxamine, and sertrailine   \- The ASEC-12                                                                No genetic association with sexual dysfunction
  rs2032582                                                     \- Different types                                                                                                                                                                                                                                                                                                                                                                                  
  rs1128503                                                     \- Men (n=133)/women                                                                                                                                                                                                                                                                                                                                                                                
  rs2235015                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  rs2235040                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  rs2032583                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Many genes \[[@B58]\]                                         Genome-wide study examining \~34 SNPs                                                                                                                                  Major depressive disorder                                                  Bupropion, buspirone, sertraline, venlafaxine, citalopram           \- PRISE                                                                      10 SNPs in *SACM1L* mediated the effects of bupropion on sexual side-effects.
  \- Different types                                                                                                                                                                                                                                                                                                                                                                                                                                                
  \- 1,439 enrolled (one-third were men.)                                                                                                                                                                                                                                                                                                                                                                                                                           
  Many genes \[[@B60]\]                                         Genome-wide study examining 421,789 SNPs                                                                                                                               Major depressive disorder                                                  Citalopram                                                          \- PRISE                                                                      All tested genes were not associated with citalopram-induced sexual dysfunction.
  \- Different types                                                                                                                                                                                                                                                                                                                                                                                                                                                
  \- 1,762 enrolled (number of men was not mentioned.)                                                                                                                                                                                                                                                                                                                                                                                                              
  *SLC6A4* \[[@B61]\]                                           5HTTLPR                                                                                                                                                                Idiopathic anejaculation                                                   \-                                                                  \- Clinician\'s assessment and IIEF-5                                         S and STin2.10 alleles were common in three patients with anejaculation.
  \- Anejaculation                                                                                                                                                                                                                                                                                                                                                                                                                                                  
  \- 3 men                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Serotonin receptor subtypes 1A, 1B, and 2C genes \[[@B47]\]   rs6295                                                                                                                                                                 Population-based sample of 1,399 male twins                                \-                                                                  \- Self-reported IELT                                                         rs11568817 in the gene encoding the 5-HT1B receptor showed an association with IELT indicating that individuals homozygous for the G allele had shorter IELTs, conferring protection against DE.
  rs11568817                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  rs130058                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  rs13212041                                                                                                                                                                                                                                                                                                                                                                                                                                                        
  rs6318                                                                                                                                                                                                                                                                                                                                                                                                                                                            
  rs3813929                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Oxytocin and vasopressin receptor genes \[[@B48]\]            19 SNPs                                                                                                                                                                Population-based sample of 1,517 men                                       \-                                                                  \- IELT, number of thrusts, anteportal ejaculation, and feeling of control.   A significant association was found with the rs75775 SNP in the oxytocin receptor gene, indicating that the heterozygote had an elevated risk of shorter IELTs, conferring protection against DE.

DE: delayed ejaculation, AE: anejaculation, SSRIs: selective serotonin re-uptake inhibitors, CYP: cytochrome P450, ASEX: Arizona Sexual Experiences Scale, 5HT: serotonin, 5-HT~2A~: subtype of the 5-HT2 receptor, GNB3: guanine nucleotide-binding protein G subunit beta-3, SLC6: solute carrier family 6, 5-HTTLPR: serotonin-transporter-linked polymorphic region, SFQ: Social Functioning Questionnaire, PRISE: Patient-Rated Inventory of Side Effects, GRIA: glutamate receptor, ABCB1: gene encoding P-glycoprotein, ASEC-12: Antidepressant Side Effect Checklist, SNP: single-nucleotide polymorphism, SACM1L: SAC1 like phosphatidylinositide phosphatase, IIEF: International Index of Erectile Function, IELT: intravaginal ejaculation latency time.

###### Medications that may delay ejaculation
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  Drug                                                              Possible mechanism                                                                                                  
  ----------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------
  1                                                                 SSRIs                                                                                                               \- Activation of a particular serotonin receptor subtype: 5HT2 receptors
  Citalopram                                                        \- Anticholinergic actions                                                                                          
  Escitalopram                                                      \- Blockade of α-1 noradrenergic receptors                                                                          
  Fluvoxamine                                                       \- Antihistaminergic actions                                                                                        
  Fluoxetine                                                        \- Antidopaminergic actions                                                                                         
  Paroxetine                                                        \- Elevated prolactin                                                                                               
  Sertraline                                                        \- Inhibitory effects on nitric oxide synthase                                                                      
  2                                                                 Other antidepressants                                                                                               \- Activation of a particular serotonin receptor subtype: 5HT2 receptors
  Amitriptyline                                                     \- Anticholinergic actions                                                                                          
  Amoxapine                                                         \- Blockade of α-1 noradrenergic receptors                                                                          
  Clomipramine                                                      \- Antihistaminergic actions                                                                                        
  Desipramine                                                       \- Antidopaminergic actions                                                                                         
  Desmethylimipramine                                               \- Elevated prolactin                                                                                               
  Duloxetine                                                        \- Inhibitory action on nitric oxide synthase                                                                       
  Imipramine                                                                                                                                                                            
  Mirtazapine                                                                                                                                                                           
  Nortriptyline                                                                                                                                                                         
  Protriptyline                                                                                                                                                                         
  Trazodone                                                                                                                                                                             
  Venlafaxine                                                                                                                                                                           
  3                                                                 Monoamine oxidase inhibitors                                                                                        \- Activation of serotonergic neurotransmission
  Isocarboxazid                                                     \- Blockade of α-1 noradrenergic receptors                                                                          
  Pargyline                                                         \- Decreased dopamine activity                                                                                      
  Phenelzine                                                                                                                                                                            
  Tranylcypromine                                                                                                                                                                       
  4                                                                 Anxiolytics                                                                                                         \- Increased central serotonergic activity
  Alprazolam                                                        \- Stimulate muscle relaxation                                                                                      
  Chlordiazepoxide                                                  \- Sedative effect                                                                                                  
  5                                                                 Neuroleptics                                                                                                        \- Inhibits dopamine activity
  Mesoridazine                                                      \- Increases the level of prolactin                                                                                 
  \- Blocks peripheral cholinergic and alpha-adrenergic receptors                                                                                                                       
  6                                                                 Diuretics                                                                                                           \- Direct effects on vascular smooth muscle cells
  Thiazide                                                          \- Reduces the response to catecholamines                                                                           
  7                                                                 Anti-inflammatory drug                                                                                              \- Blocks the enzyme cyclooxygenase, leading to inhibition of smooth muscle contraction in the vas deferens and seminal vesicles
  Naproxen                                                                                                                                                                              
  8                                                                 α1-blockers                                                                                                         \- Inhibition of α1-adrenergic receptor subtypes
  Alfuzosin                                                         \- Inhibition of smooth muscle contraction in the vas deferens and seminal vesicles.                                
  Doxazosin                                                                                                                                                                             
  Silodosin                                                                                                                                                                             
  Tamsulosin                                                                                                                                                                            
  Terazosin                                                                                                                                                                             
  9                                                                 GABA transaminase inhibitors                                                                                        \- Inhibition of GABA transaminase, leading to increased brain concentrations of GABA (inhibitory)
  Aminocaproic acid                                                                                                                                                                     
  10                                                                Antihypertensives                                                                                                   \- Reduction of central sympathetic outflow
  Bethanidine                                                       \- α-1 and β-adrenergic blocking properties                                                                         
  Guanadrel                                                         \- Produce sedation or depression                                                                                   
  Guanethidine                                                      \- Interfere with corporal smooth muscle constriction                                                               
  Labetalol                                                         \- Increased levels of prolactin                                                                                    
  Methyldopa                                                                                                                                                                            
  Prazosin                                                                                                                                                                              
  Phenoxybenzamine                                                                                                                                                                      
  Reserpine                                                                                                                                                                             
  11\.                                                              Antipsychotics                                                                                                      \- α-blocking properties and possibly also calcium channel blocking
  Chlorpromazine                                                    \- Postsynaptic dopamine antagonism, leading to inhibition of motivation and increased prolactin                    
  Haloperidol                                                       \- Agonistic serotonergic effects                                                                                   
  Perphenazine                                                      \- Histamine receptor antagonism                                                                                    
  Thioridazine                                                      \- Blockage of acetylcholine receptors                                                                              
  Butaperazine                                                                                                                                                                          
  Chlorprothixene                                                                                                                                                                       
  12\.                                                              Opiates                                                                                                             \- Blockade of presynaptic opioid receptors involved in the ejaculatory circuit.
  Methadone                                                         \- Inhibit LH and T.                                                                                                
  Tramadol                                                          \- Inhibit thyroid-stimulating hormone.                                                                             
  13\.                                                              Antiepileptics                                                                                                      \- Inhibition of calcium currents appears to lead to reduced neurotransmitter release and attenuation of postsynaptic excitability
  Carbamazepine                                                     \- Increases the level of sex hormone-binding globulin, leading to reduction of free or bioavailable testosterone   
  Gabapentin                                                                                                                                                                            
  Pregabalin                                                                                                                                                                            
  14\.                                                              Muscle relaxants                                                                                                    \- Inhibitory effect on GABA~B~ receptors at the lumbosacral spinal cord level
  Baclofen                                                          \- Inhibition of motor efferent nerves                                                                              
  15\.                                                              5-α reductase inhibitors                                                                                            \- Deleterious effect on the biosynthesis and function of neurosteroids in the central nervous system, blocking neurogenesis
  Dutasteride                                                       \- Accumulation of cholesterol in neurons, leading to neurodegeneration                                             
  Finasteride                                                                                                                                                                           
  16\.                                                              Ganglionic blocker                                                                                                  \- Blocks nicotinic receptors at sympathetic ganglia.
  Hexamethonium                                                                                                                                                                         
  17\.                                                              Alcohol                                                                                                             \- Sedative effects
  \- Increases in prolactin                                                                                                                                                             
  \- Increases estrogen                                                                                                                                                                 
  \- Decreases in 5-α-reductase                                                                                                                                                         
  \- Localized gonadal tissue damage                                                                                                                                                    

GABA: gamma-aminobutyric acid, LH: luteinizing hormone, T: testosterone.

###### Pharmacotherapy for delayed ejaculation and anejaculation
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  Drug                              Proposed mechanism                                                                                                                    Dose                       Timing                                               Common side effect
  --------------------------------- ------------------------------------------------------------------------------------------------------------------------------------- -------------------------- ---------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------
  Testosterone                      Correct hypogonadism                                                                                                                  2% testosterone solution   Applied once a day, at the same time each morning.   Pain, redness, swelling, gum or mouth irritation, breast pain, cough
  Cabergoline                       \- Dopamine agonist on D2 receptors                                                                                                   0.5 mg twice/wk            At bedtime                                           Nausea, drowsiness, cardiac valve regurgitation and heart failure
  \- Activates 5-HT2B receptors                                                                                                                                                                                                                           
  Bupropion                         Dopamine and norepinephrine reuptake inhibitor                                                                                        150\~300 mg/d              In the morning                                       Palpitations, urinary frequency, blurred vision, chest pain, agitation, psychosis
  Amantadine                        Facilitates presynaptic dopamine release and inhibits dopamine reuptake post-synaptically                                             \- As needed 100\~400 mg   \- For 2 days before sex                             Nausea, dizziness, depression, anorexia, hallucinations, compulsivity, hypotension, abnormal dreams, headache, constipation/diarrhea, arrhythmias
  \- 75\~100 mg daily               \- 2\~3 times per day                                                                                                                                                                                                 
  Cyproheptadine                    Antiserotonergic properties                                                                                                           2\~16 mg                   \- 1\~2 hours before sex                             Sedation, impaired concentration, nausea, dizziness, urinary retention, photosensitivity, rash, abdominal pain, fatigue
  \- Daily at bedtime                                                                                                                                                                                                                                     
  Midodrine                         α~1~-adrenergic receptor agonist                                                                                                      7.5\~30.0 mg               \- As needed 30\~120 minutes before sex              Dysuria, paresthesia, rigors, pruritus, piloerection, rash
  \- Daily 3 times per day                                                                                                                                                                                                                                
  Imipramine                        α~1~-adrenergic receptor agonist                                                                                                      25\~75 mg                  Daily at bedtime                                     Dry mouth, constipation, abdominal pain, blurred vision
  Ephedrine                         α~1~-adrenergic receptor agonist                                                                                                      15\~60 mg                  1 hour before sex                                    Nausea, headache, dizziness, insomnia, hypertension, hypervigilance, anxiety
  Pseudoephedrine                   α~1~-adrenergic receptor agonist                                                                                                      60\~120 mg                 2\~3 hours before sex                                Insomnia, anxiety, nausea, insomnia, tremor, urinary retention
  Yohimbine                         α~2~-adrenergic antagonist                                                                                                            20\~50 mg                  \- 1 hour before sex                                 Urinary retention, hyperglycemia, tachycardia, hypertension, irritability, dartos contraction, pleasurable tingling, tremor, nausea, dizziness
  5-HT~1A~ agonist                  \- 3 times per day                                                                                                                                                                                                    
  Buspirone                         5HT~1A~ agonist effect.                                                                                                               20\~60 mg                  Twice daily                                          Dizziness, nausea, headache, fatigue, blurred vision, numbness, weakness, abdominal pain, insomnia
  α2-adrenergic antagonist effect                                                                                                                                                                                                                         
  Oxytocin                          Actions on peripheral oxytocin or vasopressin receptors                                                                               16\~24 IU intranasally     \- During sex or sublingually before sex             Nausea, vomiting, hypertension, afibrinogenemia
  Bethanechol                       Muscarinic receptor agonist, adrenergic effects                                                                                       \- 10\~20 mg               \- As needed 1\~2 hours before sex                   Abdominal pain, nausea, diarrhea, headache, urinary urgency
  \- 30\~100 mg                     \- Twice daily                                                                                                                                                                                                        
  Lisdexamfetamine dimesylate       Releases dopamine and norepinephrine from the presynaptic nerve terminals, blocks catecholamine re-uptake by competitive inhibition   60 mg                      2 hours prior to masturbation or sex                 Raynaud\'s phenomenon (reduced blood flow to the hands and feet), and tachycardia, abdominal pain, blurred vision erectile dysfunction
  Roboxetine                        Norepinephrine reuptake inhibitor                                                                                                     4\~8 mg                    Daily                                                Insomnia, dizziness, dry mouth, constipation, nausea, and excessive sweating
